{"title":"罕见的系统性硬化症Topo I阳性和抗拓扑异构酶I （Scl-70）抗体阴性1例。","authors":"Li-Qin He, Ke-Jie Xie, Hong-Gang Sun","doi":"10.7754/Clin.Lab.2024.241124","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Systemic sclerosis is clinically heterogeneous, presenting challenges in diagnosis and treatment. ANA testing, especially positivity for the Topo I nuclear pattern, is commonly part of the diagnostic process for systemic sclerosis as it aids in identifying the presence of the disease. Additionally, anti-Scl-70 antibody is a specific serological marker for systemic sclerosis, positively correlating with disease severity and activity. This report explores the clinical characteristics and treatment strategies of patients with systemic sclerosis who are Topo I nuclear pat-tern positive and anti-Scl-70 antibody negative.</p><p><strong>Methods: </strong>Antinuclear antibodies (ANA) were detected using indirect immunofluorescence (IIF), and autoantibodies were detected using immunoblotting. Patients with IIF positivity and immunoblotting negativity for anti-Scl-70 antibody were analyzed.</p><p><strong>Results: </strong>The patient was clinically diagnosed with systemic sclerosis. Laboratory tests showed ANA Topo I nuclear pattern positivity at 1:640, while anti-Scl-70 antibodies were negative.</p><p><strong>Conclusions: </strong>Patients with systemic sclerosis who are anti-Scl-70 antibody negative but Topo I pattern positive may present different clinical manifestations and prognoses, requiring a comprehensive assessment that integrates clinical presentation, laboratory tests, and potential disease progression.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 5","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Rare Case of Systemic Sclerosis with Topo I Positivity and Anti-Topoisomerase I (Scl-70) Antibody Negativity.\",\"authors\":\"Li-Qin He, Ke-Jie Xie, Hong-Gang Sun\",\"doi\":\"10.7754/Clin.Lab.2024.241124\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Systemic sclerosis is clinically heterogeneous, presenting challenges in diagnosis and treatment. ANA testing, especially positivity for the Topo I nuclear pattern, is commonly part of the diagnostic process for systemic sclerosis as it aids in identifying the presence of the disease. Additionally, anti-Scl-70 antibody is a specific serological marker for systemic sclerosis, positively correlating with disease severity and activity. This report explores the clinical characteristics and treatment strategies of patients with systemic sclerosis who are Topo I nuclear pat-tern positive and anti-Scl-70 antibody negative.</p><p><strong>Methods: </strong>Antinuclear antibodies (ANA) were detected using indirect immunofluorescence (IIF), and autoantibodies were detected using immunoblotting. Patients with IIF positivity and immunoblotting negativity for anti-Scl-70 antibody were analyzed.</p><p><strong>Results: </strong>The patient was clinically diagnosed with systemic sclerosis. Laboratory tests showed ANA Topo I nuclear pattern positivity at 1:640, while anti-Scl-70 antibodies were negative.</p><p><strong>Conclusions: </strong>Patients with systemic sclerosis who are anti-Scl-70 antibody negative but Topo I pattern positive may present different clinical manifestations and prognoses, requiring a comprehensive assessment that integrates clinical presentation, laboratory tests, and potential disease progression.</p>\",\"PeriodicalId\":10384,\"journal\":{\"name\":\"Clinical laboratory\",\"volume\":\"71 5\",\"pages\":\"\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical laboratory\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.7754/Clin.Lab.2024.241124\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.241124","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
A Rare Case of Systemic Sclerosis with Topo I Positivity and Anti-Topoisomerase I (Scl-70) Antibody Negativity.
Background: Systemic sclerosis is clinically heterogeneous, presenting challenges in diagnosis and treatment. ANA testing, especially positivity for the Topo I nuclear pattern, is commonly part of the diagnostic process for systemic sclerosis as it aids in identifying the presence of the disease. Additionally, anti-Scl-70 antibody is a specific serological marker for systemic sclerosis, positively correlating with disease severity and activity. This report explores the clinical characteristics and treatment strategies of patients with systemic sclerosis who are Topo I nuclear pat-tern positive and anti-Scl-70 antibody negative.
Methods: Antinuclear antibodies (ANA) were detected using indirect immunofluorescence (IIF), and autoantibodies were detected using immunoblotting. Patients with IIF positivity and immunoblotting negativity for anti-Scl-70 antibody were analyzed.
Results: The patient was clinically diagnosed with systemic sclerosis. Laboratory tests showed ANA Topo I nuclear pattern positivity at 1:640, while anti-Scl-70 antibodies were negative.
Conclusions: Patients with systemic sclerosis who are anti-Scl-70 antibody negative but Topo I pattern positive may present different clinical manifestations and prognoses, requiring a comprehensive assessment that integrates clinical presentation, laboratory tests, and potential disease progression.
期刊介绍：
Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
